Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A novel binding assay for phospholipase A2.

S H Peers1, R D Taylor, R J Flower

  • 1Pharmacology Group, University of Bath, Claverton Down, U.K.

Biochemical Pharmacology
|December 15, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stem cell-derived neurons from autistic individuals with SHANK3 mutation show morphogenetic abnormalities during early development.

Molecular psychiatry·2017
Same author

Sergio Henrique Ferreira (1934-2016).

British journal of pharmacology·2017
Same author

The role of the Annexin-A1/FPR2 system in the regulation of mast cell degranulation provoked by compound 48/80 and in the inhibitory action of nedocromil.

International immunopharmacology·2016
Same author

Mechanisms for pressure-induced crystal-crystal transition, amorphization, and devitrification of SnI4.

The Journal of chemical physics·2015
Same author

On the Eicosanoid Trail with John Vane and Jack McGiff: 1974-1976. A personal reminiscence.

Prostaglandins & other lipid mediators·2015
Same author

'Annexins' themed section.

British journal of pharmacology·2015
Same journal

Dysregulation of the bile acid signaling network in non-alcoholic fatty liver disease: Mechanisms and a new paradigm of precision network pharmacology.

Biochemical pharmacology·2026
Same journal

hIMB1636-LDM, a novel anti-TROP2 ADC, exerts potent antitumor efficacy in pancreatic cancer via direct cytotoxicity and immune activation.

Biochemical pharmacology·2026
Same journal

CD55 glycosylation promotes ferroptotic stress tolerance in CD55-high triple-negative breast cancer.

Biochemical pharmacology·2026
Same journal

The role of Piezo1 in skeletal muscle physiology and pathology: from mechanosensing to precision therapy.

Biochemical pharmacology·2026
Same journal

Notch signaling in anti-VEGF resistant arteriolar choroidal neovascularization.

Biochemical pharmacology·2026
Same journal

Methylated SNHG3 lncRNA counteracts PSMD4-inhibited angiogenesis by HnRNPA2B1 SUMOylation in peripheral arterial disease.

Biochemical pharmacology·2026
See all related articles

A new assay rapidly measures pancreatic phospholipase A2 binding to lipid membranes, dependent on calcium. Only specific drugs and lipocortin inhibited binding, suggesting applications for screening anti-phospholipase agents.

Area of Science:

  • Biochemistry
  • Enzymology
  • Membrane Biophysics

Background:

  • Pancreatic phospholipase A2 (PLA2) plays a crucial role in lipid metabolism and inflammatory processes.
  • Understanding PLA2 interaction with lipid membranes is key to developing targeted therapies.
  • Existing methods for studying PLA2 binding are often complex and time-consuming.

Purpose of the Study:

  • To develop a rapid and simple assay for quantifying pancreatic phospholipase A2 binding to bilayer lipid membranes.
  • To investigate factors influencing PLA2 membrane binding, including ions, drugs, and proteins.
  • To explore the utility of this assay in screening for potential antiphospholipase agents.

Main Methods:

  • A novel assay was developed to measure the binding kinetics of pancreatic phospholipase A2 to artificial lipid bilayers.

Related Experiment Videos

  • The assay's sensitivity to calcium ions (Ca2+), various chemical agents, and purified proteins was evaluated.
  • Inhibitory effects of known phospholipase inhibitors, alcohols, detergents, and lipocortin on PLA2 binding were assessed.

    • Main Results:

    • The binding of pancreatic phospholipase A2 to lipid membranes was observed to be rapid and highly dependent on the presence of Ca2+.
    • Among tested drugs, only high concentrations of mepacrine and chlorpromazine showed inhibitory activity.
    • p-Bromophenacylbromide did not affect binding, while alcohols potentiated and detergents inhibited PLA2 binding.
    • Only lipocortin, a steroid-induced anti-phospholipase protein, effectively prevented PLA2 binding.

    Conclusions:

    • A robust and efficient assay for pancreatic phospholipase A2-membrane interaction has been established.
    • The assay provides insights into the molecular mechanisms governing PLA2 binding.
    • This method is valuable for screening and identifying novel antiphospholipase compounds and understanding their mechanism of action.